Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients

[1]  L. Notarangelo,et al.  Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.

[2]  K. Stiasny,et al.  SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity , 2021, Annals of the Rheumatic Diseases.

[3]  M. Gaboli,et al.  SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? , 2021, Journal of Clinical Immunology.

[4]  N. Freund,et al.  Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.

[5]  T. Hatahet,et al.  COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic? , 2021, Infectious disease reports.

[6]  I. Tezcan,et al.  COVID-19 in Patients with Primary Immunodeficiency , 2021, Journal of Clinical Immunology.

[7]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[8]  B. Lambrecht,et al.  Coronavirus disease 2019 in patients with inborn errors of immunity: An international study , 2020, Journal of Allergy and Clinical Immunology.

[9]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[10]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[11]  Zhihua Zheng,et al.  Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients , 2020, Cell Host & Microbe.

[12]  K. Fitzgerald,et al.  Toll-like Receptors and the Control of Immunity , 2020, Cell.

[13]  Mei-jiao Gong,et al.  Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection , 2018, Cellular Physiology and Biochemistry.

[14]  C. Cunningham-Rundles,et al.  Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. , 2018, The Journal of allergy and clinical immunology.

[15]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[16]  J. Tam,et al.  Human Coronaviruses: A Review of Virus–Host Interactions , 2016, Diseases.

[17]  J. Casanova,et al.  Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. , 2016, Blood.

[18]  S. Smeekens,et al.  Gain‐of‐function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC) , 2015, European journal of immunology.